Rationale for full-season dosing for passive antibody prophylaxis of respiratory syncytial virus

Doris Makari, Paul A. Checchia, John Devincenzo

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Palivizumab monthly injections throughout the RSV season prevent severe respiratory syncytial virus (RSV) disease in preterm infants ≤ 35 wGA. However, some RSV guidelines currently recommend stopping palivizumab after 3 months of age in the midst of the RSV season. This article evaluates the need for full-season dosing by reviewing the pharmacokinetic properties of palivizumab and RSV hospitalization (RSVH) risk as a function of chronologic age. Precise human palivizumab protective levels are not established. Clinical trials show significant interpatient variability in palivizumab serum trough concentrations. Partial season dosing is associated with increased risk of RSVH. For late-preterm infants, data suggest that the risk of RSVH remains elevated through at least 6 months of age. Monthly, full-season palivizumab dosing provides the only empirically proven protection from RSVH. In conclusion, late-preterm infants are at significant risk for RSVH through at least 6 months of age and would benefit from dosing throughout the RSV season.

Original languageEnglish (US)
Pages (from-to)607-614
Number of pages8
JournalHuman Vaccines and Immunotherapeutics
Volume10
Issue number3
DOIs
StatePublished - Jan 1 2014

Fingerprint

Respiratory Syncytial Viruses
Hospitalization
Antibodies
Premature Infants
Virus Diseases
Palivizumab
Pharmacokinetics
Clinical Trials
Guidelines
Injections
Serum

All Science Journal Classification (ASJC) codes

  • Immunology and Allergy
  • Immunology
  • Pharmacology

Cite this

Rationale for full-season dosing for passive antibody prophylaxis of respiratory syncytial virus. / Makari, Doris; Checchia, Paul A.; Devincenzo, John.

In: Human Vaccines and Immunotherapeutics, Vol. 10, No. 3, 01.01.2014, p. 607-614.

Research output: Contribution to journalArticle

@article{50839d3855404efdba0c6f418335d12c,
title = "Rationale for full-season dosing for passive antibody prophylaxis of respiratory syncytial virus",
abstract = "Palivizumab monthly injections throughout the RSV season prevent severe respiratory syncytial virus (RSV) disease in preterm infants ≤ 35 wGA. However, some RSV guidelines currently recommend stopping palivizumab after 3 months of age in the midst of the RSV season. This article evaluates the need for full-season dosing by reviewing the pharmacokinetic properties of palivizumab and RSV hospitalization (RSVH) risk as a function of chronologic age. Precise human palivizumab protective levels are not established. Clinical trials show significant interpatient variability in palivizumab serum trough concentrations. Partial season dosing is associated with increased risk of RSVH. For late-preterm infants, data suggest that the risk of RSVH remains elevated through at least 6 months of age. Monthly, full-season palivizumab dosing provides the only empirically proven protection from RSVH. In conclusion, late-preterm infants are at significant risk for RSVH through at least 6 months of age and would benefit from dosing throughout the RSV season.",
author = "Doris Makari and Checchia, {Paul A.} and John Devincenzo",
year = "2014",
month = "1",
day = "1",
doi = "10.4161/hv.27426",
language = "English (US)",
volume = "10",
pages = "607--614",
journal = "Human Vaccines and Immunotherapeutics",
issn = "2164-5515",
publisher = "Landes Bioscience",
number = "3",

}

TY - JOUR

T1 - Rationale for full-season dosing for passive antibody prophylaxis of respiratory syncytial virus

AU - Makari, Doris

AU - Checchia, Paul A.

AU - Devincenzo, John

PY - 2014/1/1

Y1 - 2014/1/1

N2 - Palivizumab monthly injections throughout the RSV season prevent severe respiratory syncytial virus (RSV) disease in preterm infants ≤ 35 wGA. However, some RSV guidelines currently recommend stopping palivizumab after 3 months of age in the midst of the RSV season. This article evaluates the need for full-season dosing by reviewing the pharmacokinetic properties of palivizumab and RSV hospitalization (RSVH) risk as a function of chronologic age. Precise human palivizumab protective levels are not established. Clinical trials show significant interpatient variability in palivizumab serum trough concentrations. Partial season dosing is associated with increased risk of RSVH. For late-preterm infants, data suggest that the risk of RSVH remains elevated through at least 6 months of age. Monthly, full-season palivizumab dosing provides the only empirically proven protection from RSVH. In conclusion, late-preterm infants are at significant risk for RSVH through at least 6 months of age and would benefit from dosing throughout the RSV season.

AB - Palivizumab monthly injections throughout the RSV season prevent severe respiratory syncytial virus (RSV) disease in preterm infants ≤ 35 wGA. However, some RSV guidelines currently recommend stopping palivizumab after 3 months of age in the midst of the RSV season. This article evaluates the need for full-season dosing by reviewing the pharmacokinetic properties of palivizumab and RSV hospitalization (RSVH) risk as a function of chronologic age. Precise human palivizumab protective levels are not established. Clinical trials show significant interpatient variability in palivizumab serum trough concentrations. Partial season dosing is associated with increased risk of RSVH. For late-preterm infants, data suggest that the risk of RSVH remains elevated through at least 6 months of age. Monthly, full-season palivizumab dosing provides the only empirically proven protection from RSVH. In conclusion, late-preterm infants are at significant risk for RSVH through at least 6 months of age and would benefit from dosing throughout the RSV season.

UR - http://www.scopus.com/inward/record.url?scp=84898427609&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84898427609&partnerID=8YFLogxK

U2 - 10.4161/hv.27426

DO - 10.4161/hv.27426

M3 - Article

VL - 10

SP - 607

EP - 614

JO - Human Vaccines and Immunotherapeutics

JF - Human Vaccines and Immunotherapeutics

SN - 2164-5515

IS - 3

ER -